Form 8-K · Current report
Vertex Pharmaceuticals 8-K, filed Sep 1, 2026
- Filed
- CIK
- 0000875320
- Accession no.
- 0000875320-26-000264
Summary
Vertex Pharmaceuticals appointed Jonathan Poole as Executive Vice President and Chief Financial Officer effective January 1, 2027, at which point Charles F. Wagner, Jr. will cease serving as Chief Financial Officer while remaining Executive Vice President and Chief Operating Officer. Poole, currently Vertex's Senior Vice President, Finance, will receive a $750,000 base salary and a 90% target annual bonus under an employment agreement and a change-of-control agreement.
Key points
- Jonathan Poole has been Senior Vice President, Finance at Vertex since March 2020 and previously served as CFO of Evelo Biosciences and of Genocea Biosciences.
- Poole has been a director and audit committee member of Acadia Pharmaceuticals since March 2026 and previously was a director and audit committee chair at Codiak Biosciences.
- Under the change-of-control agreement, qualifying terminations within 90 days before or 12 months after a change of control bring 100% of base salary and target bonus, a pro-rated target bonus, and full vesting of outstanding equity awards.
- Vertex stated there are no transactions with Poole reportable under Item 404(a) of Regulation S-K and no arrangement or understanding with any other persons regarding his appointment.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
From the filing
Item 5.02 Departure of Directors of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2026, Vertex Pharmaceuticals Incorporated (the “Company”) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer of the Company, effective January 1, 2027 (the “Effective Date”). In connection with Mr. Poole’s appointment, Charles F. Wagner, Jr., the Company’s Executive Vice President and Chief Operating & Financial Officer, will cease serving as Chief Financial Officer as of the Effective Date, but will remain Executive Vice President and Chief Operating Officer. Mr. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.